Rare Case of Olmesartan Induced Enteropathy.

Spartan Med Res J

Henry Ford Allegiance Health, Internal Medicine, Program Director, Jackson, MI.

Published: December 2017

Olmesartan (brand name Benicar) is an antihypertensive drug clinicians commonly use to treat high blood pressure. Olmesartan induced enteropathy (OSE) is a rare entity that authors first identified in 2012. The etiological basis of OSE remains unclear, although authors have suggested that this condition could be due to alternations in cell mediated immune responses induced by the drug. The objective of the case report is to describe a patient who presented with diarrhea and was eventually diagnosed with OSE. A female patient in her later 60s presented to an emergency room after two recent hospitalizations with profound diarrhea, generalized weakness and weight loss. She underwent a diagnostic workup including endoscopy and colonoscopy. The patient's endoscopy with duodenal biopsy revealed villous atrophy with attenuated and blunted villi with intraepithelial CD3 positive T lymphocytes, suggestive of gluten-induced enteropathy. When the patient's symptoms did not improve after the authors placed her on a gluten free diet for a few days, they further investigated her for secretory diarrhea, including Gastrin, Somatostatin and Vasoactive Intestinal Peptide lab values that they found to be within normal limits. Due to the patient's lack of improvement with initial treatment, the authors suspected OSE and stopped her olmesartan and the patients' symptoms gradually improved in three weeks.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746095PMC
http://dx.doi.org/10.51894/001c.6383DOI Listing

Publication Analysis

Top Keywords

olmesartan induced
8
induced enteropathy
8
rare case
4
olmesartan
4
case olmesartan
4
enteropathy olmesartan
4
olmesartan brand
4
brand benicar
4
benicar antihypertensive
4
antihypertensive drug
4

Similar Publications

Olmesartan medoxomil (OLM) is the prodrug of olmesartan, an angiotensin II type 1 receptor blocker that has antihypertensive and antioxidant activities and renal protective properties. It exhibits low water solubility, which leads to poor bioavailability and limits its clinical potential. To improve the solubility of OLM, a host-guest inclusion complex (IC) between heptakis(2,6-di-O-methyl)-β-cyclodextrin (DMβCD) and the drug substance was obtained.

View Article and Find Full Text PDF

Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.

Case Rep Med

December 2024

Department of Gastroenterology, Gastrocentro Natal, Natal, Rio Grande do Norte, Brazil.

The case involves a 63-year-old hypertensive man, taking antihypertensive medication (olmesartan) for the previous two years, who sought medical attention due to voluminous diarrhea, with several episodes per day and weight loss of 10 kg. He was submitted to a series of diagnostic procedures without elucidation and empirical treatment with unsuccessful outcome. After hospitalization for clinical stabilization and for presenting with duodenal atrophy, obtained by duodenal biopsy associated with negative markers for celiac disease, the patient was diagnosed with suspected olmesartan-induced enteropathy, showing rapid improvement of diarrhea after the drug was withdrawn, with weight regain in 6 months and normalization of the duodenal histological picture after 10 months.

View Article and Find Full Text PDF

Collagenous sprue (CS) is a rare autoimmune gastrointestinal disorder characterized by specific histologic changes in the small intestine. It often presents with more severe symptoms and a worse prognosis compared to celiac disease, including significant malabsorption, weight loss, and nutrient deficiencies. Despite treatment with a gluten-free diet, symptom improvement is limited, with only a small fraction of patients responding positively.

View Article and Find Full Text PDF

Drug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis.

Med Clin (Barc)

December 2024

Centre for Research on Drug Safety (CESME), Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, University of Valladolid (Centro de Estudios Sobre la Seguridad de los Medicamentos (CESME), Departamento de Biología Celular, Histología, Farmacología y Genética, Facultad de Medicina, Universidad de Valladolid), Valladolid, Spain; Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid (GIR Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología, Universidad de Valladolid), Spain. Electronic address:

Article Synopsis
  • Hyponatraemia can adversely affect cognitive function and increase risks for falls, fractures, and even hospital mortality.
  • The objective of the study was to identify safety signals related to drug-induced hyponatraemia and analyze cases reported in the Spanish Pharmacovigilance System.
  • The analysis revealed 659 cases of suspected drug-induced hyponatraemia, with a significant increase over five years; most cases were serious, affecting primarily elderly women, and were commonly associated with diuretics and antidepressants.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!